VTYX

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Ventyx Biosciences Inc

NASDAQ | VTYX

10.00

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 28, 2025)

$712.87M

Market Cap

-

P/E Ratio

-1.49

EPS

$10.55

52 Week High

$0.78

52 Week Low

HEALTHCARE

Sector

VTYX Chart

Recent Chart
Price Action

VTYX Technicals

Tags:

VTYX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$1.3M
Total Revenue $0
Cost Of Revenue $1.3M
Costof Goods And Services Sold $1.3M
Operating Income -$148M
Selling General And Administrative $31M
Research And Development $117M
Operating Expenses $148M
Investment Income Net -
Net Interest Income $13M
Interest Income $13M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.3M
Income Before Tax -$135M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$135M
Comprehensive Income Net Of Tax -
Ebit -$148M
Ebitda -$147M
Net Income -$135M

Revenue & Profitability

Earnings Performance

VTYX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $277M
Total Current Assets $230M
Cash And Cash Equivalents At Carrying Value $27M
Cash And Short Term Investments $27M
Inventory -
Current Net Receivables $1M
Total Non Current Assets $47M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $36M
Short Term Investments $190M
Other Current Assets $11M
Other Non Current Assets -
Total Liabilities $23M
Total Current Liabilities $13M
Current Accounts Payable $3.1M
Deferred Revenue -
Current Debt -
Short Term Debt $1.1M
Total Non Current Liabilities $9.7M
Capital Lease Obligations $11M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $11M
Other Current Liabilities $8.6M
Other Non Current Liabilities -
Total Shareholder Equity $254M
Treasury Stock -
Retained Earnings -$554M
Common Stock $7K
Common Stock Shares Outstanding $68M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$131M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $1.3M
Capital Expenditures $241K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$16M
Cashflow From Financing $122M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$135M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$1.3M
Total Revenue $0
Cost Of Revenue $1.3M
Costof Goods And Services Sold $1.3M
Operating Income -$148M
Selling General And Administrative $31M
Research And Development $117M
Operating Expenses $148M
Investment Income Net -
Net Interest Income $13M
Interest Income $13M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.3M
Income Before Tax -$135M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$135M
Comprehensive Income Net Of Tax -
Ebit -$148M
Ebitda -$147M
Net Income -$135M

VTYX News

VTYX Profile

Ventyx Biosciences Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, dedicated to developing novel small molecule therapeutics for inflammatory and autoimmune disorders. The company is advancing a promising pipeline of drug candidates that target critical pathways involved in these diseases, aiming to meet substantial unmet medical needs. With a robust emphasis on research and development, Ventyx is well-positioned to provide innovative treatment solutions that can improve patient outcomes and capitalize on emerging opportunities within the dynamic biopharmaceutical market.

LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
KTTA
+38.67%
$1.47
NVDA
-1.80%
$177.00
VINE
+10.76%
$0.39
HBI
-1.82%
$6.47
AMZE
+19.82%
$0.47
TLRY
-21.06%
$0.81
INTC
+10.18%
$40.56
BITF
+12.25%
$3.48
IPG
-1.95%
$24.57
TWOH
-15.38%
$0.00
YGMZ
-9.59%
$0.11
BYND
-3.74%
$0.98
AXDX
-61.36%
$0.03
RUBI
-26.17%
$0.15
BMNR
+4.53%
$33.18
CLSK
+12.26%
$15.10
ADAP
-15.14%
$0.05
ASST
-0.88%
$1.12
HOOD
+10.92%
$128.20
PLUG
+1.51%
$2.01
SOND
-23.45%
$0.12
SNAP
+0.72%
$7.66
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
CHR
-4.86%
$0.04
INHD
-0.97%
$0.22
ADD
-25.47%
$0.05
AAL
+0.86%
$14.05
BIYA
+17.05%
$0.29
TSLA
+0.84%
$430.17
SRM
+53.27%
$10.30
CIFR
+6.26%
$20.35
ONMD
+30.28%
$1.85
BMNU
+8.77%
$8.18
ONDS
-4.12%
$7.90
MARA
+6.30%
$11.81
WULF
+4.51%
$15.51
NIO
+0.82%
$5.50
GOOG
-1.03%
$320.28
F
+0.45%
$13.25
BURU
+10.43%
$0.24
GPUS
-8.58%
$0.30
WLGS
-5.57%
$0.04
NFLX
+1.66%
$106.14
MTSR
-0.35%
$70.50
SOFI
+4.31%
$29.72
VALE
+0.79%
$12.61
GOOGL
+0.07%
$320.18
BTBT
+2.58%
$2.38
DEFT
+9.35%
$1.52
ADTX
+21.01%
$3.80
BTG
+3.80%
$4.64
DVLT
-4.69%
$2.03
GRAB
+2.44%
$5.45
ACHR
+4.40%
$7.82
AFMD
-34.94%
$0.18
PFE
0.00%
$25.71
SMX
+250.80%
$61.04
CAN
+0.75%
$0.92
CRCL
+10.02%
$79.92
KWM
+13.63%
$0.75
APLD
+5.05%
$24.94
DNN
-0.19%
$2.55
BABA
+0.37%
$157.60
IBRX
+10.79%
$2.36
VEEE
+45.50%
$2.59
RIOT
+7.82%
$16.13
AMZN
+1.77%
$233.22
AAPL
+0.46%
$278.85
AIIO
-9.09%
$0.70
MSTR
+2.00%
$175.64
WBD
+0.50%
$24.00
AG
+12.65%
$15.22
NGD
+6.76%
$8.37
IREN
-1.32%
$47.81
RIG
+2.09%
$4.39
GRYP
-10.38%
$1.38
BAC
+1.28%
$53.67
MODV
-25.22%
$0.43
AMD
+1.53%
$217.53
RIVN
+4.20%
$16.86
SMR
+5.04%
$20.00
WMT
+1.96%
$109.10
TMC
+19.38%
$6.96
PLTR
+1.61%
$168.45
CDE
+6.76%
$17.28
ITUB
+1.82%
$7.80
AGNC
-0.66%
$10.49
CRCA
+19.56%
$4.40
KDLY
+7.20%
$0.49
T
+0.77%
$26.02
AMC
+6.30%
$2.44
NVO
+1.21%
$49.30
CRCG
+20.00%
$2.82
META
-0.41%
$633.61
SAND
-6.04%
$12.12
BBD
+0.67%
$3.70
BTE
+2.05%
$3.22
LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
KTTA
+38.67%
$1.47
NVDA
-1.80%
$177.00
VINE
+10.76%
$0.39
HBI
-1.82%
$6.47
AMZE
+19.82%
$0.47
TLRY
-21.06%
$0.81
INTC
+10.18%
$40.56
BITF
+12.25%
$3.48
IPG
-1.95%
$24.57
TWOH
-15.38%
$0.00
YGMZ
-9.59%
$0.11
BYND
-3.74%
$0.98
AXDX
-61.36%
$0.03
RUBI
-26.17%
$0.15
BMNR
+4.53%
$33.18
CLSK
+12.26%
$15.10
ADAP
-15.14%
$0.05
ASST
-0.88%
$1.12
HOOD
+10.92%
$128.20
PLUG
+1.51%
$2.01
SOND
-23.45%
$0.12
SNAP
+0.72%
$7.66
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
CHR
-4.86%
$0.04
INHD
-0.97%
$0.22
ADD
-25.47%
$0.05
AAL
+0.86%
$14.05
BIYA
+17.05%
$0.29
TSLA
+0.84%
$430.17
SRM
+53.27%
$10.30
CIFR
+6.26%
$20.35
ONMD
+30.28%
$1.85
BMNU
+8.77%
$8.18
ONDS
-4.12%
$7.90
MARA
+6.30%
$11.81
WULF
+4.51%
$15.51
NIO
+0.82%
$5.50
GOOG
-1.03%
$320.28
F
+0.45%
$13.25
BURU
+10.43%
$0.24
GPUS
-8.58%
$0.30
WLGS
-5.57%
$0.04
NFLX
+1.66%
$106.14
MTSR
-0.35%
$70.50
SOFI
+4.31%
$29.72
VALE
+0.79%
$12.61
GOOGL
+0.07%
$320.18
BTBT
+2.58%
$2.38
DEFT
+9.35%
$1.52
ADTX
+21.01%
$3.80
BTG
+3.80%
$4.64
DVLT
-4.69%
$2.03
GRAB
+2.44%
$5.45
ACHR
+4.40%
$7.82
AFMD
-34.94%
$0.18
PFE
0.00%
$25.71
SMX
+250.80%
$61.04
CAN
+0.75%
$0.92
CRCL
+10.02%
$79.92
KWM
+13.63%
$0.75
APLD
+5.05%
$24.94
DNN
-0.19%
$2.55
BABA
+0.37%
$157.60
IBRX
+10.79%
$2.36
VEEE
+45.50%
$2.59
RIOT
+7.82%
$16.13
AMZN
+1.77%
$233.22
AAPL
+0.46%
$278.85
AIIO
-9.09%
$0.70
MSTR
+2.00%
$175.64
WBD
+0.50%
$24.00
AG
+12.65%
$15.22
NGD
+6.76%
$8.37
IREN
-1.32%
$47.81
RIG
+2.09%
$4.39
GRYP
-10.38%
$1.38
BAC
+1.28%
$53.67
MODV
-25.22%
$0.43
AMD
+1.53%
$217.53
RIVN
+4.20%
$16.86
SMR
+5.04%
$20.00
WMT
+1.96%
$109.10
TMC
+19.38%
$6.96
PLTR
+1.61%
$168.45
CDE
+6.76%
$17.28
ITUB
+1.82%
$7.80
AGNC
-0.66%
$10.49
CRCA
+19.56%
$4.40
KDLY
+7.20%
$0.49
T
+0.77%
$26.02
AMC
+6.30%
$2.44
NVO
+1.21%
$49.30
CRCG
+20.00%
$2.82
META
-0.41%
$633.61
SAND
-6.04%
$12.12
BBD
+0.67%
$3.70
BTE
+2.05%
$3.22
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.